Ken Griffin Bio Affinity Technologies, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio Affinity Technologies, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 13,264 shares of BIAF stock, worth $10,611. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,264Holding current value
$10,611% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding BIAF
# of Institutions
16Shares Held
527KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA261KShares$208,6950.0% of portfolio
-
Geode Capital Management, LLC Boston, MA99.6KShares$79,6400.0% of portfolio
-
Sheaff Brock Investment Advisors, LLC46.3KShares$37,0430.0% of portfolio
-
Captrust Financial Advisors Raleigh, NC27.9KShares$22,3080.0% of portfolio
-
State Street Corp Boston, MA17.6KShares$14,0800.0% of portfolio
About bioAffinity Technologies, Inc.
- Ticker BIAF
- Exchange
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 2,727,580
- Market Cap $2.18M
- Description
- bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is b...